Shionogi & Co. Overview

  • Year Founded
  • 1878

Year Founded

  • Status
  • Public

  • Employees
  • 5,489

Employees

  • Stock Symbol
  • 4507

Stock Symbol

  • Investments
  • 35

  • Share Price
  • $17.36
  • (As of Friday Closing)

Shionogi & Co. General Information

Description

Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Shionogi engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late stage drug discovery through commercial production. The company's research and development strategy utilizes partnership and licensing opportunities with academic constituents and venture companies.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 1-8, Doshomachi 3-chome
  • Chuo-ku
  • Osaka, 541-0045
  • Japan
+81
Primary Industry
Pharmaceuticals
Other Industries
Other Devices and Supplies
Diagnostic Equipment
Stock Exchange
TKS
Corporate Office
  • 1-8, Doshomachi 3-chome
  • Chuo-ku
  • Osaka, 541-0045
  • Japan
+81

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Shionogi & Co. Stock Performance

As of 13-Jun-2025, Shionogi & Co.’s stock price is $17.36. Its current market cap is $14.8B with 851M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$17.36 $17.04 $12.47 - $17.62 $14.8B 851M 2.62M $1.31

Shionogi & Co. Financials Summary

As of 31-Mar-2025, Shionogi & Co. has a trailing 12-month revenue of $2.87B.

In Thousands,
USD
TTM 31-Mar-2025 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024 FY 2023 31-Mar-2023
EV 9,255,922 9,255,922 11,127,279 9,827,051
Revenue 2,874,159 2,874,159 3,011,153 3,151,708
EBITDA 1,164,280 1,164,280 1,187,855 1,227,403
Net Income 1,117,712 1,117,712 1,121,394 1,366,247
Total Assets 10,260,123 10,260,123 9,361,863 9,844,928
Total Debt 146,229 146,229 76,776 70,629
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Shionogi & Co. Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Shionogi & Co.‘s full profile, request access.

Request a free trial

Shionogi & Co. Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and di
Pharmaceuticals
Osaka, Japan
5,489 As of 2024

Tokyo, Japan
 

Tokyo, Japan
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Shionogi & Co. Competitors (11)

One of Shionogi & Co.’s 11 competitors is Astellas Pharma, a Corporation company based in Tokyo, Japan.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Astellas Pharma Corporation Tokyo, Japan
Kaken Pharmaceutical Corporation Tokyo, Japan
Biocon Formerly PE-Backed Bengaluru, India
SynCore Biotechnology Company Corporation Yilan City, Taiwan
Roche Corporation Basel, Switzerland
You’re viewing 5 of 11 competitors. Get the full list »

Shionogi & Co. Patents

Shionogi & Co. Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2025038019-A Parenteral preparations containing uracil derivatives Pending 09-Dec-2024
JP-2024105489-A Method for producing condensed ring derivative with mgat2 inhibitory activity Pending 10-May-2024
JP-2024100975-A Pharmaceutical composition containing dihydropyridinone derivative Pending 31-Jan-2024
JP-7674711-B1 Pharmaceutical compositions containing uracil derivatives Active 05-Oct-2023
JP-7692546-B1 Method for producing uracil derivatives Active 05-Oct-2023
To view Shionogi & Co.’s complete patent history, request access »

Shionogi & Co. Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Shionogi & Co. Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Shionogi & Co.‘s full profile, request access.

Request a free trial

Shionogi & Co. Investments & Acquisitions (35)

Shionogi & Co.’s most recent deal was a Merger/Acquisition with Akros Pharma for . The deal was made on 07-May-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Akros Pharma 07-May-2025 Merger/Acquisition Drug Discovery
PeptiStar 17-Apr-2025 Later Stage VC Drug Discovery
Ping An-Shionogi 14-Mar-2025 Secondary Transaction - Private Practice Management (Healthcare)
Cilcare 04-Dec-2024 Later Stage VC Drug Discovery
AVITA 23-Aug-2024 Early Stage VC Multimedia and Design Software
You’re viewing 5 of 35 investments and acquisitions. Get the full list »

Shionogi & Co. ESG

Risk Overview

Risk Rating

Updated April, 12, 2025

23.23 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,673

Rank

Percentile

Pharmaceuticals

Industry

of 844

Rank

Percentile

Pharmaceuticals

Subindustry

of 419

Rank

Percentile

To view Shionogi & Co.’s complete esg history, request access »

Shionogi & Co. Exits (4)

Shionogi & Co.’s most recent exit was on 03-Oct-2022 from Pixie Dust Technologies. The exit was categorized as with 5 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Pixie Dust Technologies 03-Oct-2022 Completed
  • 5 buyers
Nemesis Bioscience 15-Jun-2018 Completed
  • 6 buyers
Pioneer (Drug Discovery) 14-Sep-2015 Completed
  • 4 buyers
StemRIM 15-Dec-2014 Later Stage VC Completed
To view Shionogi & Co.’s complete exits history, request access »

Shionogi & Co. Affiliates

Subsidiaries (3)

Name Industry Location Year Founded
Ping An-Shionogi Shanghai, China 2020
Qpex San Diego, CA 2015
UMN Pharma Tokyo, Japan 2004

Shionogi & Co. FAQs

  • When was Shionogi & Co. founded?

    Shionogi & Co. was founded in 1878.

  • Where is Shionogi & Co. headquartered?

    Shionogi & Co. is headquartered in Osaka, Japan.

  • What is the size of Shionogi & Co.?

    Shionogi & Co. has 5,489 total employees.

  • What industry is Shionogi & Co. in?

    Shionogi & Co.’s primary industry is Pharmaceuticals.

  • Is Shionogi & Co. a private or public company?

    Shionogi & Co. is a Public company.

  • What is Shionogi & Co.’s stock symbol?

    The ticker symbol for Shionogi & Co. is 4507.

  • What is the current stock price of Shionogi & Co.?

    As of 13-Jun-2025 the stock price of Shionogi & Co. is $17.36.

  • What is the current market cap of Shionogi & Co.?

    The current market capitalization of Shionogi & Co. is $14.8B.

  • What is Shionogi & Co.’s current revenue?

    The trailing twelve month revenue for Shionogi & Co. is $2.87B.

  • Who are Shionogi & Co.’s competitors?

    Astellas Pharma, Kaken Pharmaceutical, Biocon, SynCore Biotechnology Company, and Roche are some of the 11 competitors of Shionogi & Co..

  • What is Shionogi & Co.’s annual earnings per share (EPS)?

    Shionogi & Co.’s EPS for 12 months was $1.31.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »